TORONTO, July 15, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that data from the Phase 2 clinical trial of ELND005 in mild to moderate Alzheimer's disease patients will be presented at the International Conference on Alzheimer's Disease (ICAD) meeting, to be held July 16-21, 2011 in Paris, France. There will be two posters and one oral presentation covering safety, efficacy, imaging, biomarker and pharmacokinetic data from the Phase 2 clinical trial.
| Poster Presentation # P2-500: |
| Safety and Efficacy Results of a Phase 2 Randomized, Placebo-Controlled, Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to Moderate Alzheimer's Disease |
| Authors: S. Salloway et al. |
| Presentation Session: Monday, July 18, 2011 |
| Poster Presentation # P2-509: |
| Population Pharmacokinetic Analysis of Plasma, Cerebrospinal Fluid, and Brain ELND005 in Patients with Mild to Moderate Alzheimer's Disease |
| Authors: J. Cedarbaum et al. |
| Presentation Session: Monday, July 18, 2011 |
| Oral Presentation # O4-06-07: |
| Imaging and Cerebrospinal Fluid Biomarker Results of a Phase 2 Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to Moderate Alzheimer's Disease |
| Authors: A. Porsteinsson et al. |
| Presentation Session: Wednesday, July 20, 2011 |
About Transition
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead product is ELND005 (AZD-103) for the treatment of Alzheimer's disease and Transition also has an emerging pipeline of innovative preclinical and clinical drug candidates. The other drugs in the pipeline that the Company is developing are for anti-inflammatory and metabolic indications. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.
For further information on Transition, visit www.transitiontherapeutics.com.